Radiation sensitizing agents in clinical radiation and chemotherapy.
Patients with bronchogenic carcinoma or with advanced pediatric solid tumours were treated with various radiation therapy schedules alone or with a new alkylating carbamate: AB 132. Drug therapy appeared to potentiate radiation therapy results without significant toxicity except for certain neurologic symptoms (myasthenia, nightmares, disturbances of taste and smell). The latter appeared to be related to acetylcholinesterase and pseudocholinesterase inhibition.
D001388:Aziridines / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy / Q000532:radiotherapy; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D010166:Palliative Care; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011897:Random Allocation
D001388:Aziridines; D001389:Azirines; D011838:Radiation-Sensitizing Agents; C024217:meturedepa